uniQure plunges 65% as 48-month Huntington’s gene therapy data misses key stat

🌐 Investing.com (Cyprus) —
uniQure plunges 65% as 48-month Huntington’s gene therapy data misses key stat

AI Summary

uniQure shares plunged 65% after 48-month results for its Huntington's disease gene therapy failed to meet a key statistical measure. The reported setback concerns clinical evidence for the experimental treatment.

Markets Health uniQure Huntington's disease gene therapy clinical trial stock plunge 48-month data

Read original source →